The Asia Pacific biosurgical agents market is primarily driven by growing surgical procedure volumes due to expanding aging population and the rising prevalence of diseases associated with aging, obesity, diabetes, and cardiovascular disease, in addition to rising awareness of the clinical benefits of these products on surgical outcomes, and the introduction of new products with enhanced features and expanded indications. However, growing concerns over product cost and competition from local competitors will limit ASP growth in this market, thus hindering revenue expansion to some extent.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for biosurgical agents in the Asia Pacific region across a 10-year period.
Growing volumes of surgical procedures will determine the overall market growth of biosurgical agents in the Asia Pacific region
Which surgical specialties contribute most to biosurgical agent revenues?
How will declining procedure volumes in certain surgical specialties affect market growth?
What impact will the expanding use of minimally invasive surgical techniques have on the biosurgical agent market?
In some Asia Pacific countries there are a few biosurgical agents that are not currently approved for sale, and the use of these products is influenced by cultural differences in the region.
Which products are currently unavailable in the Asia Pacific countries? Are these products expected to gain approval in these countries within the forecast period?
For which biosurgical agents will cultural differences negatively impact unit sales?
Compared to the US and Europe, the market for biosurgical agents in Asia Pacific countries remains underpenetrated, however competitors are targeting this region because of its growth potential.
What strategies are competitors using to target the Asia Pacific biosurgical agent market?
What types of challenges will companies face in this space, and what will they need to do to overcome these difficulties?
Product penetration by surgical specialty will influence overall market trends.
Which specialty type has seen the highest overall penetration of biosurgical agents?
Which biosurgical agent materials are most popular and drive unit sales within each specialty?
What product type accounts for the largest portion of the overall market?
Which product types will exhibit the greatest market growth and why?
The COVID-19 outbreak will have an impact on the biosurgical agent market in the Asia Pacific countries.
How will COVID-19 affect the sales and revenues of biosurgical agents in this region?
Which procedure types will be most strongly impacted by challenges associated with COVID-19?
- Biosurgical Agents - Market Insights - Asia Pacific
Author(s): Sumit Jain, MS Pharm
Sumit Jain is an analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, focusing on diagnostic imaging capital equipment and healthcare IT markets. Sumit holds a Bachelor's degree in Pharmacy from the Rajiv Gandhi Technical University, Bhopal, and a Master's degree in Pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Mohali.